{"title":"偏头痛的预防性治疗","authors":"U. Reuter","doi":"10.17925/ENR.2017.12.02.64","DOIUrl":null,"url":null,"abstract":"Support: No funding was received in the publication of this article. Shortly after the 18th Congress of the International Headache Society in Vancouver, Canada, in September 2017, Uwe Reuter participated in an expert interview. Here, he shares his insights and perspective on preventative therapies for migraine, discontinuation rates on current therapies, the need for new therapies with alternate targets and most promising potential therapies currently in development.","PeriodicalId":12047,"journal":{"name":"European neurological review","volume":"12 1","pages":"64"},"PeriodicalIF":0.0000,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Preventative Therapies for Migraine\",\"authors\":\"U. Reuter\",\"doi\":\"10.17925/ENR.2017.12.02.64\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Support: No funding was received in the publication of this article. Shortly after the 18th Congress of the International Headache Society in Vancouver, Canada, in September 2017, Uwe Reuter participated in an expert interview. Here, he shares his insights and perspective on preventative therapies for migraine, discontinuation rates on current therapies, the need for new therapies with alternate targets and most promising potential therapies currently in development.\",\"PeriodicalId\":12047,\"journal\":{\"name\":\"European neurological review\",\"volume\":\"12 1\",\"pages\":\"64\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European neurological review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17925/ENR.2017.12.02.64\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European neurological review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17925/ENR.2017.12.02.64","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Support: No funding was received in the publication of this article. Shortly after the 18th Congress of the International Headache Society in Vancouver, Canada, in September 2017, Uwe Reuter participated in an expert interview. Here, he shares his insights and perspective on preventative therapies for migraine, discontinuation rates on current therapies, the need for new therapies with alternate targets and most promising potential therapies currently in development.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
